NASDAQ:YMAB

Y-mAbs Therapeutics Competitors

$26.38

-2.11 (-7.41 %)

(As of 04/9/2021 12:00 AM ET)

Add

Compare

Today's Range

$26.14

Now: $26.38▼

$28.45

50-Day Range

$28.34

MA: $34.24▼

$42.73

52-Week Range

$26.14

Now: $26.38▼

$55.22

Volume616,328 shs

Average Volume297,563 shs

Market Capitalization$1.15 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.36

Y-mAbs Therapeutics (NASDAQ:YMAB) Vs. SAGE, BHVN, HCM, EBS, ARNA, and TPTX

Should you be buying YMAB stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Y-mAbs Therapeutics, including Sage Therapeutics (SAGE), Biohaven Pharmaceutical (BHVN), Hutchison China MediTech (HCM), Emergent BioSolutions (EBS), Arena Pharmaceuticals (ARNA), and Turning Point Therapeutics (TPTX).

Y-mAbs Therapeutics vs. Sage Therapeutics Stock

Y-mAbs Therapeutics (NASDAQ:YMAB) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Comparatively, 4.8% of Sage Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Y-mAbs Therapeutics and Sage Therapeutics' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47
Sage Therapeutics	$6.87 million	651.04	$-680,240,000.00	($13.38)	-5.73

Y-mAbs Therapeutics has higher earnings, but lower revenue than Sage Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Y-mAbs Therapeutics and Sage Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	0	2	6	0	2.75
Sage Therapeutics	0	8	8	0	2.50

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, suggesting a potential upside of 120.41%. Sage Therapeutics has a consensus price target of $87.0625, suggesting a potential upside of 13.64%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Y-mAbs Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Y-mAbs Therapeutics and Sage Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%
Sage Therapeutics	-7,706.84%	-63.81%	-56.64%

Summary

Y-mAbs Therapeutics beats Sage Therapeutics on 7 of the 13 factors compared between the two stocks.

Y-mAbs Therapeutics vs. Biohaven Pharmaceutical Stock

Y-mAbs Therapeutics (NASDAQ:YMAB) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

Profitability

This table compares Y-mAbs Therapeutics and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%
Biohaven Pharmaceutical	N/A	-1,091.41%	-120.85%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Y-mAbs Therapeutics and Biohaven Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	0	2	6	0	2.75
Biohaven Pharmaceutical	0	2	10	0	2.83

Y-mAbs Therapeutics currently has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Biohaven Pharmaceutical has a consensus price target of $96.4545, indicating a potential upside of 39.00%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Biohaven Pharmaceutical.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Biohaven Pharmaceutical has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Earnings & Valuation

This table compares Y-mAbs Therapeutics and Biohaven Pharmaceutical's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47
Biohaven Pharmaceutical	N/A	N/A	$-528,800,000.00	($10.91)	-6.36

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 38.4% of Y-mAbs Therapeutics shares are owned by company insiders. Comparatively, 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Y-mAbs Therapeutics beats Biohaven Pharmaceutical on 7 of the 11 factors compared between the two stocks.

Y-mAbs Therapeutics vs. Hutchison China MediTech Stock

Hutchison China MediTech (NASDAQ:HCM) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Hutchison China MediTech and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hutchison China MediTech	N/A	N/A	N/A
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%

Analyst Recommendations

This is a summary of recent ratings and price targets for Hutchison China MediTech and Y-mAbs Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hutchison China MediTech	0	0	2	0	3.00
Y-mAbs Therapeutics	0	2	6	0	2.75

Hutchison China MediTech presently has a consensus price target of $40.00, indicating a potential upside of 36.80%. Y-mAbs Therapeutics has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Given Y-mAbs Therapeutics' higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Hutchison China MediTech.

Risk and Volatility

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hutchison China MediTech and Y-mAbs Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hutchison China MediTech	$204.89 million	20.77	$-106,020,000.00	($0.80)	-36.55
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47

Y-mAbs Therapeutics has lower revenue, but higher earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Y-mAbs Therapeutics beats Hutchison China MediTech on 7 of the 12 factors compared between the two stocks.

Y-mAbs Therapeutics vs. Emergent BioSolutions Stock

Emergent BioSolutions (NYSE:EBS) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Emergent BioSolutions and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emergent BioSolutions	12.50%	26.68%	12.70%
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%

Valuation & Earnings

This table compares Emergent BioSolutions and Y-mAbs Therapeutics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent BioSolutions	$1.11 billion	3.73	$54.50 million	$2.91	26.58
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47

Emergent BioSolutions has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

80.2% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are held by institutional investors. 14.1% of Emergent BioSolutions shares are held by company insiders. Comparatively, 38.4% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for Emergent BioSolutions and Y-mAbs Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent BioSolutions	0	2	5	0	2.71
Y-mAbs Therapeutics	0	2	6	0	2.75

Emergent BioSolutions presently has a consensus price target of $109.8333, indicating a potential upside of 42.00%. Y-mAbs Therapeutics has a consensus price target of $58.1429, indicating a potential upside of 120.41%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than Emergent BioSolutions.

Risk and Volatility

Emergent BioSolutions has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Summary

Emergent BioSolutions beats Y-mAbs Therapeutics on 8 of the 13 factors compared between the two stocks.

Y-mAbs Therapeutics vs. Arena Pharmaceuticals Stock

Y-mAbs Therapeutics (NASDAQ:YMAB) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Y-mAbs Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%
Arena Pharmaceuticals	N/A	-33.17%	-30.41%

Valuation & Earnings

This table compares Y-mAbs Therapeutics and Arena Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47
Arena Pharmaceuticals	$806.43 million	4.96	$397.55 million	$7.69	8.62

Arena Pharmaceuticals has higher revenue and earnings than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Y-mAbs Therapeutics and Arena Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	0	2	6	0	2.75
Arena Pharmaceuticals	0	0	15	0	3.00

Y-mAbs Therapeutics presently has a consensus target price of $58.1429, indicating a potential upside of 120.41%. Arena Pharmaceuticals has a consensus target price of $91.80, indicating a potential upside of 38.48%. Given Y-mAbs Therapeutics' higher probable upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than Arena Pharmaceuticals.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Summary

Arena Pharmaceuticals beats Y-mAbs Therapeutics on 8 of the 12 factors compared between the two stocks.

Y-mAbs Therapeutics vs. Turning Point Therapeutics Stock

Y-mAbs Therapeutics (NASDAQ:YMAB) and Turning Point Therapeutics (NASDAQ:TPTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Y-mAbs Therapeutics and Turning Point Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Y-mAbs Therapeutics	N/A	-74.98%	-66.70%
Turning Point Therapeutics	N/A	-23.81%	-23.08%

Valuation & Earnings

This table compares Y-mAbs Therapeutics and Turning Point Therapeutics' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Y-mAbs Therapeutics	N/A	N/A	$-81,030,000.00	($2.30)	-11.47
Turning Point Therapeutics	N/A	N/A	$-72,130,000.00	($2.99)	-26.40

Turning Point Therapeutics is trading at a lower price-to-earnings ratio than Y-mAbs Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Y-mAbs Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Turning Point Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Y-mAbs Therapeutics and Turning Point Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Y-mAbs Therapeutics	0	2	6	0	2.75
Turning Point Therapeutics	0	0	7	0	3.00

Y-mAbs Therapeutics presently has a consensus target price of $58.1429, indicating a potential upside of 120.41%. Turning Point Therapeutics has a consensus target price of $153.7143, indicating a potential upside of 94.70%. Given Y-mAbs Therapeutics' higher probable upside, equities analysts clearly believe Y-mAbs Therapeutics is more favorable than Turning Point Therapeutics.

Institutional and Insider Ownership

53.2% of Y-mAbs Therapeutics shares are held by institutional investors. Comparatively, 81.3% of Turning Point Therapeutics shares are held by institutional investors. 38.4% of Y-mAbs Therapeutics shares are held by insiders. Comparatively, 23.2% of Turning Point Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Turning Point Therapeutics beats Y-mAbs Therapeutics on 6 of the 11 factors compared between the two stocks.